Given that liraglutide was reported to reduce the risk of cardiovascular events in patients with T2DM in the LEADER trial [100] and in a 2019 meta-analysis [101], in addition to other GLP-1 RAs, it is reasonable to suppose that liraglutide (along with other GLP-1RAs [69,70]) might become an important treatment option in NAFLD patients, especially if they are obese or have T2DM. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.